What is Pendulum Therapeutics?
Headquartered in San Francisco, Pendulum Therapeutics operates at the intersection of microbiology, computational biology, and clinical medicine. As the first evidence-based microbiome company, it utilizes a proprietary innovation platform to identify specific mechanisms of action within the human gut. Its flagship product, Pendulum Glucose Control, represents a paradigm shift in dietary management, offering a clinically validated medical probiotic designed to assist in the regulation of A1C and blood sugar levels for individuals with type 2 diabetes. By bridging the gap between discovery and commercialization, the company is effectively transforming complex genomic data into actionable, therapeutic interventions that address chronic metabolic conditions.
How much funding has Pendulum Therapeutics raised?
Pendulum Therapeutics has raised a total of $117.5M across 4 funding rounds:
Series A
$18.5M
Series B
$35M
Series C
$54M
Other Financing Round
$10M
Series A (2017): $18.5M with participation from True Ventures, Morgan Noble, and Khosla Ventures
Series B (2019): $35M led by Sequoia Capital
Series C (2021): $54M supported by True Ventures, Steamboat Ventures, Meritech, and Khosla Ventures
Other Financing Round (2023): $10M featuring Fonterra
Key Investors in Pendulum Therapeutics
Sequoia Capital
A premier global venture capital firm with an unparalleled track record of partnering with entrepreneurs to build market-leading companies across the technology and healthcare sectors.
True Ventures
A founder-first venture capital firm that provides early-stage capital and strategic guidance to help build enduring technology and AI-driven enterprises.
Khosla Ventures
A venture firm focused on breakthrough technologies, providing strategic advice and capital to entrepreneurs in sectors ranging from health and biotech to enterprise software.
What's next for Pendulum Therapeutics?
With the support of its latest strategic financing, Pendulum Therapeutics is well-positioned to accelerate its clinical validation pipeline and expand its commercial footprint. The company's focus remains on deepening its understanding of the microbiome's role in human health, potentially unlocking new therapeutic avenues beyond glucose management. As it transitions into a more mature enterprise phase, the firm will likely prioritize scaling its manufacturing capabilities and broadening its distribution channels to meet the growing demand for personalized, science-backed health products. The continued backing from top-tier venture firms suggests a robust roadmap for long-term market leadership in the rapidly evolving biotech landscape.
See full Pendulum Therapeutics company page
